Abstract
Initiation and progression of liver cancer are driven by a subpopulation of tumor cells—the cancer stem cells (CSCs). Thus, targeted therapy of CSCs holds great promise for providing important new impetus to tumor biology and clinical oncology. CD133 is one of the important surface markers of liver CSCs. Cell-penetrating peptide (CPP) is defined as the peptide sequence capable of transporting various molecules efficiently into cells across membranes. In this study, paclitaxel-loaded nanoparticles (NPs) are modified with anti-CD133 antibody and CPP (Polyarginine) to construct multifunctional drug delivery system for targeting liver CSCs and efficient endocytosis. NPs were prepared by emulsification–solvent evaporation method and modified by carbodiimide hydrochloride and hydroxysuccinimide (EDC/NHS). The physicochemical characteristics of NPs (i.e., encapsulation efficiency, particle size distribution, morphology, release in vitro) were determined. Cellular uptake of NPs was investigated. Using the hepatocellular carcinoma (HCC) cell lines (HepG2 and Huh7), cell survival assay was performed to assess anti-tumor activity in vitro of NPs. Particle size distribution of NPs was between 50 and 200 nm. Drug-loaded NPs showed spherical morphology and higher encapsulation efficiency. The release behavior of paclitaxel from the polymer NPs showed an immediate burst effect. The accumulation of NPs modified with the ligands depended on passive and active targeting. Drug-loaded NPs caused cytotoxicity on HepG2 and Huh7 cells. NPs modified with both ligands maximized the selectivity and therapeutic effect for liver CSCs. This study provided a new idea for HCC therapy in the future.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baetke SC, Lammers T, Kiessling F (2015) Applications of nanoparticles for diagnosis and therapy of cancer. Br J Radiol 88(1054):20150207. https://doi.org/10.1259/bjr.20150207
Barbato L, Bocchetti M, Di Biase A, Regad T (2019) Cancer Stem Cells and Targeting Strategies. Cells 8(8):926. https://doi.org/10.3390/cells8080926
Bazak R, Houri M, ssEIAchy, Kamel S, Refaat T. (2015) Cancer active targeting by nanoparticles: a comprehensive review of literature. J Cancer Res Clin Oncol 141(5):769–784. https://doi.org/10.1007/s00432-014-1767-3
Bhise K, Sau S, Alsaab H, Kashaw SK, Tekade RK, Iyer AK (2017) Nanomedicine for cancer diagnosis and therapy: advancement, success and structure-activity relationship. Ther Deliv 8(11):1003–1018. https://doi.org/10.4155/tde-2017-0062
Clara JA, Monge C, Yang Y, Takebe N (2020) Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update. Nat Rev Clin Oncol 17(4):204–232. https://doi.org/10.1038/s41571-019-0293-2
Clarke MF (2019) Clinical and Therapeutic Implications of Cancer Stem Cells. N Engl J Med 380(23):2237–2245. https://doi.org/10.1056/NEJMra1804280
Couvreur P (2013) Nanoparticles in drug delivery: past, present and future. Adv Drug Deliv Rev 65(1):21–23. https://doi.org/10.1016/j.addr.2012.04.010
Craig AJ, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A (2020) Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 17(3):139–152. https://doi.org/10.1038/s41575-019-0229-4
Forner A, Reig M, Bruix J (2018) Hepatocellular carcinoma. Lancet 391(10127):1301–1314. https://doi.org/10.1016/S0140-6736(18)30010-2
Ghanbari-Movahed M, Shiri Varnamkhasti B, Shourian M (2022) Inhibiting Notch activity in breast cancer stem cells by functionalized gold nanoparticles with gamma-secretase inhibitor DAPT and vitamin C. Chem Pap 76:1157–1170. https://doi.org/10.1007/s11696-021-01936-w
Guidotti G, Brambilla L, Rossi D (2017) Cell-Penetrating Peptides: From Basic Research to Clinics. Trends Pharmacol Sci 38(4):406–424. https://doi.org/10.1016/j.tips.2017.01.003
Irvine DJ, Dane EL (2020) Enhancing cancer immunotherapy with nanomedicine. Nat Rev Immunol 20(5):321–334. https://doi.org/10.1038/s41577-019-0269-6
Jang JW, Song Y, Kim SH, Kim J, Seo HR (2017) Potential mechanisms of CD133 in cancer stem cells. Life Sci 184:25–29. https://doi.org/10.1016/j.lfs.2017.07.008
Jin C, Wu H, Liu J, Bai L, Guo G (2007) The effect of paclitaxel-loaded nanoparticles with radiation on hypoxic MCF-7 cells. J Clin Pharm Ther 32:41–47. https://doi.org/10.1111/j.1365-2710.2007.00796.x
Jin C, Bai L, Wu H, Song W, Guo G, Dou K (2009) Cytotoxicity of paclitaxel incorporated in PLGA nanoparticles on hypoxic human tumor cells. Pharm Res 26:1776–1784. https://doi.org/10.1007/s11095-009-9889-z
Jin C, Qian N, Zhao W, Yang W, Bai L, Wu H et al (2010) Improved therapeutic effect of DOX–PLGA–PEG micelles decorated with bivalent fragment HAb18 F(ab’)2 for hepatocellular carcinoma. Biomacromol 11:2422–2431. https://doi.org/10.1021/bm1005992
Jin C, Yang Z, Yang J, Li H, He Y, An J et al (2014) Paclitaxel-loaded nanoparticles decorated with anti-CD133 antibody: a targeted therapy for liver cancer stem cells. J Nanopart Res 16(1):2157–2171. https://doi.org/10.1007/s11051-013-2157-5
Jin C, Bai L, Lin L, Wang S, Yin X (2018) Paclitaxel-loaded nanoparticles decorated with bivalent fragment HAb18 F(ab’)2 and cell penetrating peptide for improved therapeutic effect on hepatocellular carcinoma. Artif Cells Nanomed Biotechnol 46(5):1076–1084. https://doi.org/10.1080/21691401.2017.1360325
Khamehchian S, Nikkhah M, Madani R, Hosseinkhani S (2016) Enhanced and selective permeability of gold nanoparticles functionalized with cell penetrating peptide derived from maurocalcine animal toxin. J Biomed Mater Res A 104(11):2693–2700. https://doi.org/10.1002/jbm.a.35806
Kim T, Hyeon T (2014) Applications of inorganic nanoparticles as therapeutic agents. Nanotechnology 25(1):012001. https://doi.org/10.1088/0957-4484/25/1/012001
Montané X, Bajek A, Roszkowski K, Montornés JM, Giamberini M, Roszkowski S et al (2020) Encapsulation for Cancer Therapy. Molecules 25(7):1605. https://doi.org/10.3390/molecules25071605
Nio K, Yamashita T, Kaneko S (2017) The evolving concept of liver cancer stem cells. Mol Cancer 16(1):4. https://doi.org/10.1186/s12943-016-0572-9
Skwarczynski M, Toth I (2019) Cell-penetrating peptides in vaccine delivery: facts, challenges and perspectives. Ther Deliv 10(8):465–467. https://doi.org/10.4155/tde-2019-0042
Swaminathan SK, Roger E, Toti U, Niu L, Ohlfest JR, Panyam J (2013) CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J Control Release 171(3):280–287. https://doi.org/10.1016/j.jconrel.2013.07.014
Wang K, Sun D (2018) Cancer stem cells of hepatocellular carcinoma. Oncotarget 9(33):23306–23314. https://doi.org/10.18632/oncotarget.24623
Wang W, Abbad S, Zhang Z, Wang S, Zhou J, Lv H (2015) Cell-penetrating Peptides for Cancer-targeting Therapy and Imaging. Curr Cancer Drug Targets 15(4):337–351. https://doi.org/10.2174/1568009615666150211104524
Wang Z, Tan J, McConville C, Kannappan V, Tawari PE, Brown J et al (2017) Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells. Nanomedicine 13(2):641–657. https://doi.org/10.1016/j.nano.2016.08.001
Wyatt EA, Davis ME (2020) Nanoparticles Containing a Combination of a Drug and an Antibody for the Treatment of Breast Cancer Brain Metastases. Mol Pharm 17(2):717–721. https://doi.org/10.1021/acs.molpharmaceut.9b01167
Xiao Y, Lin M, Jiang X, Ye J, Guo T, Shi Y et al (2017) The Recent Advances on Liver Cancer Stem Cells: Biomarkers, Separation, and Therapy. Anal Cell Pathol (amst) 2017:5108653. https://doi.org/10.1155/2017/5108653
Yagci T, Cetin M, Ercin PB (2017) Cancer Stem Cells in Hepatocellular Carcinoma. J Gastrointest Cancer 48(3):241–245. https://doi.org/10.1007/s12029-017-9960-7
Yao CG, Martins PN (2020) Nanotechnology Applications in Transplantation Medicine. Transplantation 104(4):682–693. https://doi.org/10.1097/TP.0000000000003032
Yohan D, Chithrani BD (2014) Applications of nanoparticles in nanomedicine. J Biomed Nanotechnol 10(9):2371–2392. https://doi.org/10.1166/jbn.2014.2015
Zhao H, Wu M, Zhu L, Tian Y, Wu M, Li Y et al (2018) Cell-penetrating Peptide-modified Targeted Drug-loaded Phase-transformation Lipid Nanoparticles Combined with Low-intensity Focused Ultrasound for Precision Theranostics against Hepatocellular Carcinoma. Theranostics 8(7):1892–1910. https://doi.org/10.7150/thno.22386
Acknowledgements
This work was funded by Xi'an Health Commission Project (No. J201903071).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
There are no Conflicts of Funding and Interests for all authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Jin, C., Bai, L. & Wang, S. Multifunctional nanoparticles for targeting liver cancer stem cells and efficient endocytosis. Chem. Pap. 77, 1395–1403 (2023). https://doi.org/10.1007/s11696-022-02566-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11696-022-02566-6